首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
【24h】

Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.

机译:预测中度至高危疾病和多种不利危险因素的男性中前列腺癌的死亡率。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To determine whether the number of unfavorable risk factors could be used to predict the risk of prostate cancer-specific mortality (PCSM) among men with intermediate- to high-risk prostate cancer. METHODS AND MATERIALS: We studied 1,063 men who underwent radical prostatectomy (n = 559), external beam radiotherapy (n = 288), or radiotherapy plus androgen suppression therapy (n = 116) for prostate cancer between 1965 and 2002. Fine and Gray's regression analysis was used to determine whether an increasing number of unfavorable risk factors (prostate-specific antigen level >10 ng/mL, Gleason score of >or=7, clinical Stage T2b or greater, or pretreatment prostate-specific antigen velocity >2.0 ng/mL/y) was associated with the interval to PCSM and all-cause mortality. RESULTS: Median follow-up was 5.6 years. Compared with those with one risk factor, the adjusted hazard ratio for PCSM was 2.3 (95% confidence interval 1.1-4.8; p = 0.03) for two risk factors, 5.4 (95% confidence interval 2.7-10.7; p < 0.0001) for three risk factors, and 13.6 (95% confidence interval 6.3-29.2; p < 0.0001) for all four risk factors. The 5-year cumulative incidence of PCSM was 2.4% for one factor, 2.4% for two factors, 7.0% for three factors, and 14.7% for all four factors. Prostate cancer deaths as a proportion of all deaths was 19% for one factor, 33% for two factors, 53% for three factors, and 80% for four factors. CONCLUSION: The number of unfavorable risk factors was significantly associated with PCSM. Prostate cancer was the major cause of death in men with at least three risk factors. Therefore, these men should be considered for clinical trials designed to assess whether survival is prolonged with the addition of novel agents to current standards of practice.
机译:目的:确定不利危险因素的数量是否可用于预测中高危前列腺癌男性的前列腺癌特异性死亡(PCSM)风险。方法和材料:我们研究了1965年至2002年之间接受前列腺癌根治术(n = 559),外部束放射疗法(n = 288)或放射疗法加雄激素抑制疗法(n = 116)的1,063名男性。Fine和Gray的回归分析用于确定是否存在越来越多的不利危险因素(前列腺特异性抗原水平> 10 ng / mL,格里森评分>或等于7,临床T2b或更高或治疗前前列腺特异性抗原速度> 2.0 ng / mL mL / y)与PCSM的间隔时间和全因死亡率相关。结果:中位随访时间为5.6年。与具有一个危险因素的危险因素相比,针对两个危险因素的PCSM调整后危险比为2.3(95%置信区间1.1-4.8; p = 0.03),对于三个危险因素为5.4(95%置信区间2.7-10.7; p <0.0001)危险因素,以及所有四个危险因素的13.6(95%置信区间6.3-29.2; p <0.0001)。 PCSM的5年累积发生率是一个因素为2.4%,两个因素为2.4%,三个因素为7.0%,所有四个因素为14.7%。前列腺癌死亡在所有死亡中所占的比例为:一个因素为19%,两个因素为33%,三个因素为53%,四个因素为80%。结论:不良危险因素的数量与PCSM显着相关。前列腺癌是具有至少三个危险因素的男性死亡的主要原因。因此,应考虑对这些男性进行临床试验,以评估在目前的实践标准中添加新型药物是否能延长生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号